Company: WHWK
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001628280-25-020311
Chunk: 8

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 8
---
 |
| Voting Results                             |     | We will announce preliminary results at the Annual Meeting. We will report final results by filing a Form 8-K within four business days after the Annual Meeting. If final results are not available at that time, we will provide preliminary voting results in the Form 8-K and will provide the final results in an amendment to the Form 8-K as soon as they become available.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div align='center'>4</div>

<div align='center'>5</div>

### PROPOSAL ONE

### ELECTION OF DIRECTORS

#### Board Structure
Our Board currently consists of ten (10) members and is divided into three staggered classes of directors. One class is elected each year at the annual meeting of stockholders for a term of three years. The term of the Class II directors expires at the Annual Meeting. The term of the Class I directors expires at the 2027 annual meeting and the term of the Class III directors expires at the 2026 annual meeting. Directors are elected to hold office for a three-year term and until the election and qualification of their successors in office, or until such director’s earlier resignation, death or removal.

#### Director Nominees
Based on the recommendation of the Nominating and Corporate Governance Committee, our Board has nominated Anupam Dalal, M.D., Mohammad Hirmand, M.D. and David Lennon, Ph.D. for election as the Class II directors to serve for a three-year term ending at the 2028 annual meeting and until their successors are elected and qualified, or until their earlier resignation, death or removal. Drs. Dalal, Hirmand and Lennon are current members of our Board and have consented to serve, if elected. Based on the recommendation of the Nominating and Corporate Governance Committee, our Board has decided not to nominate Karin Hehenberger, M.D., Ph.D. for re-election to our Board at the Annual Meeting after the expiration of her term at the Annual Meeting. This decision is not the result of any disagreement with us or our Board. As such, following the Annual Meeting, the size of our Board will be reduced to nine (9) members.

Unless you direct otherwise through your proxy voting instructions, the persons named as proxies will vote all proxies received "FOR" the election of each nominee. If any nominee is unable or unwilling to serve at the time of the Annual Meeting, the persons named as proxies may vote for a substitute nominee chosen by the